August 12th 2022
Closing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.
August 5th 2022
Shared insight on the CheckMate 9LA trial, which combined dual IO therapy with chemotherapy in the setting of advanced non–small cell lung cancer.
Expert perspectives on the CheckMate 227 clinical trial, which combined ipilimumab and nivolumab IO therapy in patients with advanced NSCLC.
July 29th 2022
A brief discussion on when it is appropriate to discontinue chemoimmunotherapy in patients with advanced non–small cell lung cancer.
Shifting their focus to chemoimmunotherapy combinations in advanced NSCLC, experts review clinical trial data from KEYNOTE-189, IMpower150, and EMPOWER-Lung 3.
July 22nd 2022
Shared insight on the optimal selection and use of single-agent immunotherapy guided by the testing and expression of PD-L1.
A brief review of AEs seen with immunotherapy in advanced non–small cell lung cancer followed by advice on how to nuance safety data in this setting.
July 21st 2022
Neal Edward Ready, MD, PhD, discusses the practice implications of nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer.
July 15th 2022
Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.
Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.
August 25th 2021
Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.
The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.
Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.
August 18th 2021
Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.
Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.
August 11th 2021
The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.
Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.
August 4th 2021
Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.
July 28th 2021
How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.